Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Andrea Facciabene, Gregory T. Motz, George Coukos
Cancer Research (2012) Vol. 72, Iss. 9, pp. 2162-2171
Open Access | Times Cited: 742

Showing 1-25 of 742 citing articles:

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian, Mario Sznol, David F. McDermott, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 10, pp. 1020-1030
Open Access | Times Cited: 2097
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
Eran Elinav, Roni Nowarski, Christoph A. Thaiss, et al.
Nature reviews. Cancer (2013) Vol. 13, Iss. 11, pp. 759-771
Closed Access | Times Cited: 1763
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1305
NF-κB, an Active Player in Human Cancers
Yifeng Xia, Shen Shen, Inder M. Verma
Cancer Immunology Research (2014) Vol. 2, Iss. 9, pp. 823-830
Open Access | Times Cited: 1020
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum, Hua Liang, Liufu Deng, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 6, pp. 365-379
Closed Access | Times Cited: 870
Cytokine patterns in patients with cancer: a systematic review
Bodo Lippitz
The Lancet Oncology (2013) Vol. 14, Iss. 6, pp. e218-e228
Closed Access | Times Cited: 852
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H.C. Baumeister, Gordon J. Freeman, Glenn Dranoff, et al.
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 539-573
Closed Access | Times Cited: 830
Deubiquitylating enzymes and drug discovery: emerging opportunities
Jeanine A. Harrigan, Xavier Jacq, Niall M.B. Martin, et al.
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 1, pp. 57-78
Open Access | Times Cited: 716
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy, Karen M. Kaluza, Gordon J. Freeman, et al.
Cancer Research (2013) Vol. 73, Iss. 12, pp. 3591-3603
Open Access | Times Cited: 684
Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer
Jun Xu, Ligeng Xu, Chenya Wang, et al.
ACS Nano (2017) Vol. 11, Iss. 5, pp. 4463-4474
Closed Access | Times Cited: 643
Nanoparticle‐Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy
Qian Chen, Jiawen Chen, Zhijuan Yang, et al.
Advanced Materials (2019) Vol. 31, Iss. 10
Closed Access | Times Cited: 594
Deciphering and Reversing Tumor Immune Suppression
Greg Motz, George Coukos
Immunity (2013) Vol. 39, Iss. 1, pp. 61-73
Open Access | Times Cited: 546
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott, Jeffrey A. Sosman, Mario Sznol, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 8, pp. 833-842
Closed Access | Times Cited: 539
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Malte Mohme, Sabine Riethdorf, Klaus Pantel
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 3, pp. 155-167
Closed Access | Times Cited: 529
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Veronica Huber, Chiara Camisaschi, Angela Berzi, et al.
Seminars in Cancer Biology (2017) Vol. 43, pp. 74-89
Open Access | Times Cited: 506
Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice
Wenwen Yue, Liang Chen, Luodan Yu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 497
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E Overacre-Delgoffe, Maria Chikina, Rebekah Dadey, et al.
Cell (2017) Vol. 169, Iss. 6, pp. 1130-1141.e11
Open Access | Times Cited: 492
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
Won Suk Lee, Hannah Yang, Hong Jae Chon, et al.
Experimental & Molecular Medicine (2020) Vol. 52, Iss. 9, pp. 1475-1485
Open Access | Times Cited: 459
Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Jo Marie Tran Janco, Purushottam Lamichhane, Lavakumar Karyampudi, et al.
The Journal of Immunology (2015) Vol. 194, Iss. 7, pp. 2985-2991
Open Access | Times Cited: 399
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Yang Liu, Yinping Dong, Li Kong, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 379
Effect of tumor cells and tumor microenvironment on NK‐cell function
Massimo Vitale, Claudia Cantoni, Gabriella Pietra, et al.
European Journal of Immunology (2014) Vol. 44, Iss. 6, pp. 1582-1592
Open Access | Times Cited: 358
The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity
Chengxian Xu, Shaogang Sun, Travis S. Johnson, et al.
Cell Reports (2021) Vol. 35, Iss. 11, pp. 109235-109235
Open Access | Times Cited: 326
Light‐Triggered In Situ Gelation to Enable Robust Photodynamic‐Immunotherapy by Repeated Stimulations
Zhouqi Meng, Xuanfang Zhou, Jun Xu, et al.
Advanced Materials (2019) Vol. 31, Iss. 24
Closed Access | Times Cited: 322
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li, Changshun Shao, Yufang Shi, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 321
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Alice L. Hung, Russell Maxwell, Debebe Theodros, et al.
OncoImmunology (2018), pp. e1466769-e1466769
Open Access | Times Cited: 294
Page 1 - Next Page

Scroll to top